Published by Iain Gilbert on 26th February 2026
(Sharecast News) - Drugmaker GSK said on Thursday that regulators in Japan and China had accepted two separate new drug applications for review, covering investigational treatments targeting chronic hepatitis B and cholestatic pruritus in primary biliary cholangitis.